A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Articles|October 15, 2001
- BioPharm International-10-01-2001
- Volume 14
- Issue 10
Qualification of Network Components and Validation of Networked Systems
Author(s)Rory Budihandojo, Ludwig Huber
by Ludwig Huber at Agilent Technologies GmbH and Rory Budihandojo To comply with 21 CFR Part 11, your networked systems require the same validation and qualification steps as those for a single computer. Shared servers and multiple access also add requirements that are unique to networks. Italicized words in this article are defined in the "The Glossaryy" on the last page of the online version.
Advertisement
Articles in this issue
about 25 years ago
Statistical Tools for Setting In-Process Acceptance Criteriaabout 25 years ago
Managing Your Career: Recruiter-Proof Your Organizationabout 25 years ago
Inside Washington: Crisis and Costs Grip Biotech Industryabout 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Advertisement
Advertisement
Trending on BioPharm International
1
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
4
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
5